As of May 2024 bluebird bio has a market cap of $0.19 Billion. This makes bluebird bio the world's 6957th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.19 B | -25.36% |
2023 | $0.26 B | -53.64% |
2022 | $0.57 B | -18.08% |
2021 | $0.70 B | -75.61% |
2020 | $2.87 B | -40.89% |
2019 | $4.85 B | -10.52% |
2018 | $5.43 B | -37.87% |
2017 | $8.74 B | 279.73% |
2016 | $2.30 B | -2.86% |
2015 | $2.36 B | -20.12% |
2014 | $2.96 B | 490.57% |
2013 | $0.50 B |
On May 17th, 2024 the market cap of bluebird bio was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Sanofi SNY | $122.00 B | 61,358.41% | ๐ซ๐ท France |
Merck MRK | $332.27 B | 167,274.69% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.13 B | -32.10% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | $10.93 B | 5,406.43% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | $19.3 M | -90.28% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $14.72 B | 7,318.28% | ๐บ๐ธ USA |